press center press release

Parnell Pharmaceuticals (NASDAQ: PARN) to Ring The NASDAQ Stock Market Opening Bell in Celebration of IPO




Parnell Pharmaceuticals (Nasdaq:PARN), a fully integrated veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on The NASDAQ Stock Market today, June 18. 

In honor of the occasion, Robert Joseph, Chief Executive Officer will ring the Opening Bell.


NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio


Wednesday, June 18, 2014 – 9:15 a.m. to 9:30 a.m. ET  

Parnell Pharmaceuticals Contact:

Erika Vikor

NASDAQ MarketSite:

Christine Barna

(646) 441-5310

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0


Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

For photos from ceremonies and events visit our Instagram Page:

For news tweets, please visit our Twitter page at:

For exciting viral content and ceremony photos visit Tumblr Page:


A webcast of the NASDAQ Opening Bell will be available at: or


To obtain a hi-resolution photograph of the Market Open, please go to and click on the market open of your choice.

About Parnell Pharmaceuticals (NASDAQ: PARN):

Parnell is a fully integrated veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with revolutionary digital technologies – iKAM and mySYNCH. These digital applications are designed to optimize the benefits veterinarians and animal owners can obtain from Parnell's best-in-class products.. Parnell believes its unique combination of pharmaceuticals with cutting edge technology solutions establishes them as a business partner with veterinarians and enhances the quality of life of companion animals and production efficiencies for farmers.

In the last decade, Parnell has significantly enhanced its core competencies across the entire pharmaceutical value chain including the 2012 FDA approval of its sterile manufacturing facility located in Sydney, Australia which provides a low-cost and reliable supply of their own products and with 75% available capacity Parnell is seeking contract manufacturing and pipeline expansion opportunities.

Parnell intends to leverage these core competencies to bring at least seven new products to market over the next five years, addressing up to 12 indications, with a particular focus on the companion animal sector. Parnell's fully-integrated, pharmaceutical value chain positions them to effectively and efficiently leverage current product portfolios, expand and scale their pipeline and elicit attractive in-licensing or acquisition opportunities.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit


In This Story


Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more